CVE:DMT Small Pharma (DMT) Stock Price, News & Analysis C$0.15 -0.01 (-6.25%) As of 10/20/2023 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Small Pharma Stock (CVE:DMT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Small Pharma alerts:Sign Up Key Stats Today's RangeC$0.15▼C$0.1650-Day RangeC$0.15▼C$0.1552-Week RangeC$0.06▼C$0.22Volume1.89 million shsAverage Volume296,159 shsMarket CapitalizationC$50.37 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Small Pharma Inc., a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Its clinical program is based on N,N, dimethyltryptamine, a naturally occurring psychoactive molecule. The company's product includes SPL026, which is in clinical Phase IIa for the treatment of major depressive disorder; and SPL028, an injectable formulation of deuterated DMT, which is in Phase 1 clinical trial, as well as SPL801B, an oral dosage. Its preclinical stage programs include SPL029, an oral formulation of a tryptamine to treat depressive disorder. The company is headquartered in London, the United Kingdom. As of October 23, 2023, Small Pharma Inc. operates as a subsidiary of Cybin Inc. Read More Receive DMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Small Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DMT Stock News HeadlinesInhaled DMT produces rapid and lasting antidepressant effects in treatment-resistant depressionMay 17, 2025 | msn.comMilestone Pharmaceuticals Prepares for CARDAMYST ApprovalNovember 13, 2024 | markets.businessinsider.com“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.August 28 at 2:00 AM | InvestorPlace (Ad)Pro Golfers Turn To Psychedelics For Focus Boost And Anxiety ReliefNovember 8, 2024 | benzinga.comInsight: How Asian pharma suppliers cash in on Ozempic copiesOctober 31, 2024 | reuters.comLTR Pharma’s SPONTAN Nasal Spray Poised for Global ImpactOctober 29, 2024 | markets.businessinsider.comNew Schizophrenia Drug Represents Promise Of Pharmaceutical InnovationOctober 15, 2024 | forbes.comIrish-Polish Startup Unveils Free EU-GxP Compliant Seed-To-Sale Platform For Small Medical Cannabis ProducersOctober 15, 2024 | msn.comSee More Headlines DMT Stock Analysis - Frequently Asked Questions How have DMT shares performed this year? Small Pharma's stock was trading at C$0.15 at the beginning of 2025. Since then, DMT shares have increased by 0.0% and is now trading at C$0.15. How do I buy shares of Small Pharma? Shares of DMT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Small Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Small Pharma investors own include Bombardier, Inc. Class B (BBD.B), Arrival (ARVL), Air Canada (AC), Beyond Meat (BYND), Biosig Technologies (BSGM), Aveanna Healthcare (AVAH) and Actinium Pharmaceuticals (ATNM). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:DMT CIKN/A Webwww.smallpharma.co.uk Phone44 78 1212 1944FaxN/AEmployees13Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$19.31 million Net MarginsN/A Pretax MarginN/A Return on Equity-116.90% Return on Assets-66.00% Debt Debt-to-Equity Ratio5.95 Current Ratio2.63 Quick Ratio6.28 Sales & Book Value Annual Sales-C$1.16 thousand Price / Sales-43,343.80 Cash FlowC$0.13 per share Price / Cash Flow1.13 Book ValueC$0.03 per share Price / Book5.00Miscellaneous Outstanding Shares335,770,000Free FloatN/AMarket CapC$50.37 million OptionableNot Optionable Beta0.86 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (CVE:DMT) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Small Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Small Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.